Completed PHASE1 INTERVENTIONAL NCT00001409

Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications

A Phase I/II Pilot Study of the Safety of the Adoptive Transfer of Syngeneic Gene-Modified Cytotoxic T Lymphocytes in HIV Infected Identical Twins

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Acquired Immunodeficiency Syndrome HIV Infection

Interventions Interleukin-2

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Sep 30, 1994 Completion: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00001409, this PHASE1 trial focuses on Acquired Immunodeficiency Syndrome and HIV Infection and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 5 times since 1994, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States